Literature DB >> 22736773

Association of FOXE1 polyalanine repeat region with papillary thyroid cancer.

Martyn Bullock1, Emma L Duncan, Christine O'Neill, Lyndal Tacon, Mark Sywak, Stan Sidhu, Leigh Delbridge, Diana Learoyd, Bruce G Robinson, Marian Ludgate, Roderick J Clifton-Bligh.   

Abstract

CONTEXT: Polyalanine tract variations in transcription factors have been identified for a wide spectrum of developmental disorders. The thyroid transcription factor forkhead factor E1 (FOXE1) contains a polymorphic polyalanine tract with 12-22 alanines. Single-nucleotide polymorphisms (SNP) close to this locus are associated with papillary thyroid cancer (PTC), and a strong linkage disequilibrium block extends across this region.
OBJECTIVE: The objective of the study was to assess whether the FOXE1 polyalanine repeat region was associated with PTC and to assess the effect of polyalanine repeat region variants on protein expression, DNA binding, and transcriptional function on FOXE1-responsive promoters.
DESIGN: This was a case-control study.
SETTING: The study was conducted at a tertiary referral hospital. PATIENTS AND METHODS: The FOXE1 polyalanine repeat region and tag SNP were genotyped in 70 PTC, with a replication in a further 92 PTC, and compared with genotypes in 5767 healthy controls (including 5667 samples from the Wellcome Trust Case Control Consortium). In vitro studies were performed to examine the protein expression, DNA binding, and transcriptional function for FOXE1 variants of different polyalanine tract lengths.
RESULTS: All the genotyped SNP were in tight linkage disequilibrium, including the FOXE1 polyalanine repeat region. We confirmed the strong association of rs1867277 with PTC (overall P = 1 × 10(-7), odds ratio 1.84, confidence interval 1.31-2.57). rs1867277 was in tight linkage disequilibrium with the FOXE1 polyalanine repeat region (r(2) = 0.95). FOXE1(16Ala) was associated with PTC with an odds ratio of 2.23 (confidence interval 1.42-3.50; P = 0.0005). Functional studies in vitro showed that FOXE1(16Ala) was transcriptionally impaired compared with FOXE1(14Ala), which was not due to differences in protein expression or DNA binding.
CONCLUSIONS: We have confirmed the previous association of FOXE1 with PTC. Our data suggest that the coding polyalanine expansion in FOXE1 may be responsible for the observed association between FOXE1 and PTC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22736773     DOI: 10.1210/jc.2012-1456

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  27 in total

1.  Relationships of FOXE1 and ATM genetic polymorphisms with papillary thyroid carcinoma risk: a meta-analysis.

Authors:  Jie Kang; Xian-Zhao Deng; You-Ben Fan; Bo Wu
Journal:  Tumour Biol       Date:  2014-04-24

2.  TITF1 and TITF2 loci variants indicate significant associations with thyroid cancer.

Authors:  Peiliang Geng; Juanjuan Ou; Jianjun Li; Yunmei Liao; Ning Wang; Ganfeng Xie; Rina Sa; Chen Liu; Lisha Xiang; Houjie Liang
Journal:  Endocrine       Date:  2015-07-25       Impact factor: 3.633

3.  Common genetic variants on FOXE1 contributes to thyroid cancer susceptibility: evidence based on 16 studies.

Authors:  Yixin Zhuang; Weixin Wu; Han Liu; Weixin Shen
Journal:  Tumour Biol       Date:  2014-04-18

4.  Association between FOXP3 gene polymorphisms and risk of differentiated thyroid cancer in Chinese Han population.

Authors:  Weichao Jiang; Lei Zheng; Lijuan Xu; Yang Zhang; Xingxin Liu; Lihua Hu; Xiaobei Wang
Journal:  J Clin Lab Anal       Date:  2016-11-28       Impact factor: 2.352

5.  The investigation of foxe1 variations in papillary thyroid carcinoma.

Authors:  Erkan Somuncu; Adem Karatas; Sina Ferahman; Neslihan Saygili; Eren Yilmaz; Oguz Ozturk; Metin Kapan
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

6.  Identification of a novel germline FOXE1 variant in patients with familial non-medullary thyroid carcinoma (FNMTC).

Authors:  Joana S Pereira; Joana Gomes da Silva; Rute Alexandra Tomaz; António Evaristo Pinto; Maria João Bugalho; Valeriano Leite; Branca Maria Cavaco
Journal:  Endocrine       Date:  2014-11-09       Impact factor: 3.633

7.  A single nucleotide polymorphism associated with isolated cleft lip and palate, thyroid cancer and hypothyroidism alters the activity of an oral epithelium and thyroid enhancer near FOXE1.

Authors:  Andrew C Lidral; Huan Liu; Steven A Bullard; Greg Bonde; Junichiro Machida; Axel Visel; Lina M Moreno Uribe; Xiao Li; Brad Amendt; Robert A Cornell
Journal:  Hum Mol Genet       Date:  2015-02-04       Impact factor: 6.150

8.  FOXE1 association with differentiated thyroid cancer and its progression.

Authors:  Marissa Penna-Martinez; Friederike Epp; Heinrich Kahles; Elizabeth Ramos-Lopez; Nora Hinsch; Martin-Leo Hansmann; Ivan Selkinski; Frank Grünwald; Katharina Holzer; Wolf O Bechstein; Stefan Zeuzem; Christian Vorländer; Klaus Badenhoop
Journal:  Thyroid       Date:  2014-01-29       Impact factor: 6.568

9.  Patterns of FOXE1 expression in papillary thyroid carcinoma by immunohistochemistry.

Authors:  Andrey Bychkov; Vladimir Saenko; Masahiro Nakashima; Norisato Mitsutake; Tatiana Rogounovitch; Alyaksandr Nikitski; Florence Orim; Shunichi Yamashita
Journal:  Thyroid       Date:  2013-06-21       Impact factor: 6.568

10.  Genetic predisposition to papillary thyroid carcinoma: involvement of FOXE1, TSHR, and a novel lincRNA gene, PTCSC2.

Authors:  Huiling He; Wei Li; Sandya Liyanarachchi; Jaroslaw Jendrzejewski; Mukund Srinivas; Ramana V Davuluri; Rebecca Nagy; Albert de la Chapelle
Journal:  J Clin Endocrinol Metab       Date:  2015-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.